2019
1115PD Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040
Cohen E, Harrington K, Soulières D, Le Tourneau C, Licitra L, Burtness B, Bal T, Juco J, Aurora-Garg D, Huang L, Swaby R, Emancipator K. 1115PD Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040. Annals Of Oncology 2019, 30: v452-v453. DOI: 10.1093/annonc/mdz252.007.Peer-Reviewed Original ResearchTumor proportion scoreSecond-line treatmentSubsidiary of MerckMerck SeronoPD-L1Dohme Corp.Boehringer IngelheimTrial conductEfficacy outcomesMerck SharpEfficacy resultsDeath ligand 1 (PD-L1) expressionNeck squamous cell carcinomaGenentech/RocheObjective response rateSecond-line therapyLigand 1 expressionPD-L1 expressionPD-L1 statusProgression-free survivalSquamous cell carcinomaStandard of careSimilar survival resultsExpression levelsEuropean Medicines Agency1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Yu J, Tsay C, Sasaki C, Son Y, Decker R, Mehra S, Burtness B. 1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Annals Of Oncology 2019, 30: v457. DOI: 10.1093/annonc/mdz252.019.Peer-Reviewed Original ResearchNon-cancer mortalityExternal beam radiationOverall survivalCancer mortalityOral cavityOropharyngeal squamous cell cancerBrachytherapy-treated patientsGenentech/RocheImpact of brachytherapyReceipt of brachytherapySecond primary cancerEffect of comorbiditySquamous cell cancerProportional hazards regressionSingle-institution studyHigher cancer mortalityBeam radiationElectronic medical recordsGlaxo Smith KlineBristol-Myers SquibbEligible patientsOropharynx SCCHPV statusPrimary malignancySecondary outcomes
2014
LBA31 A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc)
Chow L, Burtness B, Weiss J, Berger R, Eder J, Gonzalez E, Pulini J, Johnson J, Dolled-Filhart M, Emancipator K, Lunceford J, Pathiraja K, Gause C, Cheng J, Seiwert T. LBA31 A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc). Annals Of Oncology 2014, 25: v1. DOI: 10.1093/annonc/mdu438.32.Peer-Reviewed Original ResearchOverall response ratePD-L1 expressionDrug-related adverse eventsAdverse eventsRECIST v1.1Subsidiary of MerckBristol-Myers SquibbInvestigator reviewAntitumor activityCommon drug-related adverse eventsAdvisory board membershipHigh PD-L1 expressionBoehringer IngelheimMerck SharpGenentech/RochePhase Ib studyPrimary end pointDrug-related deathsMeasurable diseaseMedian OSMedian PFSMetastatic HNCAdvanced HNCUnacceptable toxicityComplete response